Crane (CR) Q2 2026 earnings review
Record Earnings and Raised Guidance Mask Underlying PFT Weakness
Crane delivered a blowout Q2 2026, driving a 25.6% YoY revenue surge and raising full-year adjusted EPS guidance to $6.85-$7.05. However, a deeper look reveals a tale of two segments: Aerospace & Advanced Technologies (AAT) is accelerating rapidly with 13.3% core growth, while Process Flow Technologies (PFT) is relying entirely on recent acquisitions to mask a 1.4% core sales decline. Despite the organic volume drag in PFT, strong operational execution expanded overall adjusted margins to 21.3%. The market is likely to reward the guidance raise, but the divergence in segment health requires close monitoring.
🐂 Bull Case
The Aerospace & Advanced Technologies segment continues to be a powerhouse, delivering 13.3% core sales growth and driving total core backlog up 5% sequentially.
The four recent acquisitions (Druck, Panametrics, Reuter-Stokes, and optek-Danulat) contributed nearly 20% to total sales growth and are performing ahead of internal expectations.
🐻 Bear Case
Despite a reported 20.9% segment sales increase, PFT's core sales actually declined 1.4%, exposing underlying weakness in its legacy end markets.
The integration of Druck is acting as a margin headwind for AAT, compressing the segment's adjusted operating margin by 80 basis points YoY despite strong volume and pricing.
⚖️ Verdict: 🟢
Bullish. The 13.3% core growth in AAT and the successful integration of major acquisitions provide a clear runway for earnings. PFT's volume declines are a concern, but management's ability to extract 80 bps of margin expansion from a shrinking organic revenue base proves the efficacy of the Crane Business System.
Key Themes
Aerospace & Advanced Technologies Accelerating
AAT remains the primary growth engine for Crane. Segment sales surged 31.3% YoY to $339.1M, underpinned by a robust 13.3% core growth rate. Strong defense and commercial aerospace demand continue to fuel this trajectory, pushing the segment's backlog to a record $1.27 billion (up 11% YoY on a core basis).
M&A Integration Outperforming
The inorganic growth strategy is paying immediate dividends. The acquisitions of Druck, Panametrics, Reuter-Stokes, and optek-Danulat contributed 19.8% to total company sales growth. Management explicitly noted these units are delivering stronger growth and margin expansion than originally modeled, validating the $1.15B+ capital deployment from early 2026.
PFT Margin Execution Under Pressure
PFT adjusted operating margin expanded 80 basis points to 22.2% YoY. This is a crucial victory, as it occurred despite lower organic volumes and expected dilution from recent acquisitions. The expansion points to rigorous cost discipline, productivity gains, and effective value-pricing strategies offsetting cyclical weakness.
PFT Core Volume Reversing
The headline for PFT looks great (+20.9% sales growth), but the underlying data contradicts the positive narrative: core sales fell 1.4% YoY. The segment is entirely dependent on its 21.5% acquisition contribution to stay afloat. If end-market demand doesn't inflect soon, the legacy PFT portfolio risks acting as a severe anchor on future organic growth.
AAT Margin Dilution from Druck
While AAT volume is exceptional, adjusted operating margins decelerated, falling 80 basis points to 25.8%. Management confirmed this compression was primarily driven by expected dilution from the Druck acquisition, which fully offset the favorable net pricing and higher volumes from the legacy business. Accelerating Druck's profitability to the segment average is now a key execution requirement.
Macro Sluggishness in Chemical End Markets
The negative core growth in PFT reflects ongoing macro sluggishness, particularly in chemical and industrial processing markets. While niche sectors like space launch cryogenics and Reuter-Stokes' nuclear portfolio are performing well, broader industrial capital expenditure delays continue to suppress legacy PFT order books.
Exclusion of Tariff Recoveries
Crane recorded a significant GAAP benefit from $18.7 million in tariff refunds during the quarter. Management correctly adjusted this out of their non-GAAP operating profit metrics ($154.3M), ensuring that the reported 21.3% adjusted margin reflects true operational performance rather than one-time regulatory windfalls.
Other KPIs
A highly stable result for the quarter. Operating cash flow from continuing operations generated $122.3M, funding $14.6M in CapEx. This positions the company well to rapidly de-lever from its Q1 acquisition spree, ending the quarter with a cash balance of $350.4M and total debt of $1,098.4M ($90M of which was repaid subsequent to quarter-end).
Accelerating. Up 5% sequentially on a core basis. The backlog provides massive visibility into 2026 and 2027. AAT accounts for $1.26 billion of this total, securing the company's medium-term revenue baseline against potential macro shocks.
Guidance
Accelerating. Raised from the prior range of $6.65-$6.85. The midpoint of $6.95 implies roughly 15% YoY growth versus FY25, indicating that management expects Q2's operational outperformance to compound through the back half of the year.
Accelerating. Raised from 'low-to-mid-20%'. Importantly, the core sales growth component is now expected to hit 5-6%, the absolute high end of their previous 4-6% guidance range, proving that AAT strength is more than offsetting PFT weakness.
Stable to slightly accelerating. Increased from prior commentary of '~23.0%'. This implies that margin dilution from the recent acquisitions will be aggressively counteracted by legacy business leverage and accelerated cost synergies.
Key Questions
PFT Core Inflection
PFT core sales declined 1.4% this quarter. Are you seeing any green shoots in the European chemical market, or should investors expect PFT organic growth to remain negative through the rest of 2026?
Druck Margin Progression
Druck dilution compressed AAT margins by 80 bps this quarter. What is the specific timeline for the Crane Business System to lift Druck's margin profile to the AAT segment average of 26%?
Tariff Strategy Post-Refund
With the $18.7M tariff refund secured, what is your ongoing exposure to new supply chain tariffs, and what pricing actions are preemptively in place to protect the 23%+ segment margin target?
Capital Deployment Priorities
Having repaid $90 million in debt post-quarter end, your balance sheet is rapidly reloading. Are you prioritizing further deleveraging, or is the M&A pipeline actionable enough to expect another major deal before year-end?